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From Infancy to Adolescence: Fifteen Years of Continuous
Treatment With Hydroxyurea in Sickle Cell Anemia
Jane S. Hankins, MD, MS, Banu Aygun, MD, Kerri Nottage, MD, MPH,
Courtney Thornburg, MD, MS, Matthew P. Smeltzer, MS, PhD,
Russell E. Ware, MD, PhD, and Winfred C. Wang, MD

Abstract: Despite documented laboratory and clinical benefits of
hydroxyurea for children with sickle cell anemia (SCA), the drug’s
long-term safety and efficacy remains poorly defined. The HUSOFT
trial and extension study examined feasibility, toxicity, and hematological efficacy of hydroxyurea in infants with SCA.
This report describes HUSOFT participants who have continued
hydroxyurea therapy for 15 years. With IRB approval, medical records
were reviewed for clinical, laboratory, and growth parameters.
Twenty-eight infants enrolled in the original 2-year HUSOFT study
received open-label liquid hydroxyurea at 20 mg/kg/day; 17 completed
the extension study with dose escalation to 30 mg/kg/day. Eight of these
17 (6 girls and 2 boys, all HbSS) have continued on daily hydroxyurea for
at least 15 years (median age at last follow-up 17.6 years) without
interruption. All hematologic indices (Hb concentration, mean corpuscular volume (MCV), fetal hemoglobin) showed sustained effect after
15 years. The median maximum tolerated dose of hydroxyurea has
decreased from 30 to 26 mg/kg/day (range 19.5–31.2); neutropenia
[absolute neutrophil count (ANC) < 1.0  109/L] prompting temporary
drug discontinuation occurred a total of 10 times in 4 subjects and there
was no severe neutropenia (ANC < 0.5  109/L). Growth rates over
15 years continued at the 50th percentile for both height and weight,
and puberty occurred without delay (age range 10–14 years). There were
5.1 vaso-occlusive events (pain and acute chest syndrome)/100 patient
years, 7.3 packed red blood cell transfusions/100 patient years. No malignancies, strokes, or deaths occurred. At last follow up, all subjects were at
appropriate grade level (10–12 grade) with no history of repeated grades.
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A cohort of young teenagers with SCA who initiated treatment in
infancy have had sustained and continued hematological benefits for a
decade and a half. Growth and sexual development are normal and
comparable to the general pediatric population. Continuous hydroxyurea
therapy since infancy appears safe and efficacious in SCA.
(Medicine 93(28):e215)
Abbreviations: ACS = acute chest syndrome, ANC = neutrophil
count, FDA = Federal Drug Administration, GFR = glomerular
filtration rate, Hb = hemoglobin, HbF = fetal hemoglobin,
HUSOFT = hydroxyurea safety and organ toxicity study,
HUSTLE = hydroxyurea study of long-term effects study, LaSHS
= Laikon study of hydroxyurea in sickle cell syndromes, LDH =
lactate dehydrogenase, MCV = corpuscular volume, MRA =
magnetic resonance angiography, MRI = magnetic resonance
imaging, MPR = medication possession ratio, MSH = multicenter
study of hydroxyurea in SCA, MTD = maximum tolerated dose,
SCA = sickle cell anemia, TCD = transcranial doppler
ultrasonography, WBC = white blood cell count.

INTRODUCTION

H

ydroxyurea has been utilized for more than 20 years to
prevent complications of sickle cell anemia (SCA). Due to
its ability to increase fetal hemoglobin (HbF) production and
reduce white blood cell count (WBC) and platelet counts,
among other effects, hydroxyurea can ameliorate the disease
phenotype.1–3 Among adults, the long-term use of hydroxyurea
and its impact on mortality were examined in participants of the
multicenter study of hydroxyurea in SCA (MSH) as well as in a
Greek cohort who participated in the Laikon study of hydroxyurea in sickle cell syndromes (LaSHS).4,5 Both studies had
prolonged follow-up (approximately 17 years) and both showed
elevated HbF, reduced acute events, and decreased mortality
with hydroxyurea utilization. However, the drug’s long-term
efficacy and toxicity have not been described in a pediatric
cohort treated with hydroxyurea from a very young age.
The hydroxyurea safety and organ toxicity (HUSOFT) study
was a phase I/II clinical trial in a cohort of 28 infants with SCA,
not selected for severity, who started treatment at 6 to 24 months
of age. HUSOFT demonstrated that administration of liquid
hydroxyurea at 20 mg/kg/day for 2 years was feasible, well
tolerated, and associated with expected hematologic effects
and possibly improved splenic function.6 Twenty-one of these
children then entered a follow-up study, receiving hydroxyurea dose escalation to maximum tolerated dose (MTD) or
30 mg/kg/day (whichever is highest). Eleven of these 21 children
completed an additional 4 years of follow-up, and had sustained
hematologic effects, fewer acute vaso-occlusive events and
less splenic dysfunction compared with untreated historical
controls.7 Although children treated with hydroxyurea for up
www.md-journal.com |
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to 7 years have been described,8,9 the present study provides data
on 8 children from the original HUSOFT trial, who were treated
with hydroxyurea therapy for a minimum of 15 years at MTD
starting at a very young age. We have examined the risks and
benefits of long-term continuous hydroxyurea treatment in this
cohort.

METHODS
Patient Selection and Evaluations
In the HUSOFT extension study cohort, 11 subjects who
started hydroxyurea in infancy completed 6 years of therapy.7
Since that report, three subjects have discontinued hydroxyurea:
1 due to parental request, 1 due to the patient’s decision to
interrupt therapy, and 1 due to loss of follow-up (Figure 1). The
data for the 8 patients who have continuously been treated with
hydroxyurea for 15 years without interruption are presented.
The clinical and laboratory data of those original HUSOFT
subjects who received therapy for longer than 6 years were
collected under the longitudinal observational hydroxyurea
study of long-term effects (HUSTLE, NCT00305175), which
prospectively monitors the function of the spleen, brain, and
kidneys at 3-year intervals, in addition to growth and development, during hydroxyurea therapy. These subjects were followed clinically with standard-of-care visits every 1 or 2 months
at St. Jude Children’s Research Hospital (St. Jude) or Duke
University, but all research evaluations including organ function
were conducted at St. Jude.
Complete blood counts were obtained at every clinic visit
and chemistry panel and HbF measurements (using high
performance liquid chromatography) were performed every
2 months. Post-pubertal females were offered contraception
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and/or received monthly pregnancy tests. Adherence was not
formally measured, but was estimated by calculation of the
medication possession ratio (MPR). This was determined by
dividing the amount of drug dispensed (in days of treatment
covered) by the interval period between refills (in days), providing a measure of the proportion of days of medication
availability. An MPR >80% has been considered a surrogate
for good adherence with hydroxyurea therapy.10 Pill counts
were not consistently available for these subjects.
Spleen function was assessed by 99mTc-liver/spleen scan,
and uptake was graded as normal, decreased, or absent. The
presence or absence of silent cerebral infarcts (SCI) and cerebral
vasculopathy were assessed by brain magnetic resonance imaging (MRI) and angiography (MRA). Transcranial Doppler ultrasonography (TCD) was performed to monitor velocity in the
major cerebral arteries. Renal function was evaluated through
quantification of urine protein and measurement of glomerular
filtration rate (GFR) by 99mTc-DTPA plasma clearance. Data
regarding sickle cell-related clinical events, including pain, acute
chest syndrome (ACS), stroke, and blood transfusions, and
hematologic toxicity were captured at routine visits by review
of emergency department, hospital, and clinic records.
The present study was approved by the St. Jude Institutional Review Board IRB in accordance with the current version
of the Helsinki Declaration. All HUSTLE participants had
informed consent signed by their parents or legal guardians.
Assent was obtained from all participants older than 7 years
of age.

Statistical Considerations
The mean and standard deviation of laboratory parameters,
including Hb concentration, mean corpuscular volume (MCV),

1996
1HUSOFT

study

28 Subjects
Age range 6–24 months
2 years

2HUSOFT

extension study

Discontinued hydroxyurea due to:
Non-adherence = 2
Parental request = 3
Switched to transfusions due to TIA = 1
Fatal splenic sequestration = 1

21 Subjects

Discontinued hydroxyurea due to:
Non-adherence = 4
Initiated transfusions due to recurrent ACS = 1
Parental request = 4
Fatal pneumococcal sepsis = 1

4 years
11 Subjects

9 years

Present study

Discontinued hydroxyurea due to:
Lost to follow-up = 1
Adolescent request = 1
Parental request = 1

8 Subjects
Age range 15–16 years
TIA: transient ischemic attack
ACS: acute chest syndrome

2012

1Wang

WC, et al. J Pediatr 2001;139(6):790−796.

2Hankins

JS, et al. Blood 2005;106(7):2269−2275.

FIGURE 1. Reasons for premature discontinuation of hydroxyurea therapy.
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Year 15

Hb F, WBC, absolute neutrophil count (ANC), reticulocyte
count, platelet count, and lactate dehydrogenase (LDH), were
calculated for each of the 15 years of hydroxyurea therapy.
Weight and height were plotted using standard pediatric growth
curves.

In the 9 years since the last report, HUSOFT subjects have,
on average, remained at the 50th percentile for both height and
weight. They started pubertal development between 10 and
14 years of age (median of 12 years), and in which is the
expected age in the general pediatric population. All subjects
were attending school at an appropriate grade level (grades 10,
11, or 12) with no history of repeated grades.

Organ Function
Two subjects underwent splenectomy during the first
6 years of hydroxyurea therapy. Of the remaining 6, 1 (17%)
had normal splenic uptake on Tc99 LSscan, and the other 5 had
absent splenic function. None of the subjects had proteinuria
(>300 mcg albumin/g creatinine), but microalbuminuria was
present in all; the median protein/creatinine ratio was 120 mcg
#

2014 Lippincott Williams & Wilkins

9.2  1.6
106.6  9.5
8.2  2.6
4487.5  2091.1
316.8  83.8
19.4  4.7
7.1  3.3
520.8  170.4
26.3  13.9
0.4  0.1
143.5  30.1
25.3  3.9
9.3  1.2
100.4  10.7
8.0  3.2
3961.8  1627.5
375.1  147.2
17.5  6.3
6.7  3.4
407.8  99.9
25.3  13.4
0.4  0.0
140.7  17.5
28.6  1.8
9.2  1.7
101.7  10.3
11.0  5.9
5000.4  3872.5
341.6  132.9
19.8  8.1
6.5  4.4
1234.3  428.6
21.0  10.4
0.4  0.1
Not done
30.0  0
9.2  1.5
97.4  8.8
10.5  4.8
4693.8  3272.9
333.8  144.2
23.7  7.2
9.9  5.7
1243.6  294.3
25.8  13.4
0.4  0.1
Not done
20.0  0

Year 9
Year 6

9.0  1.0
89.2  11.1
9.2  3.0
4130.1  1746.6
368.9  94.1
19.7  3.9
7.6  6.1
954.3  269.5
25.4  8.8
0.3  0.1
Not done
20.0  0

Growth and Development

8.5  1.2
82.5  7.8
12.5  3.9
4853.9  2461.1
446.1  93.5
22.5  8.0
7.2  4.3
947.7  99.3
21.8  8.4
0.3  0.1
Not done
0

Toxicity from hydroxyurea was rare. Neutropenia
ANC) < 1.0  109/L prompting temporary drug discontinuation
occurred 10 times in 4 subjects over a median of 15.9 years. No
severe neutropenia (ANC < 0.5  109/L) was recorded. Two
episodes of thrombocytopenia (in 2 subjects) with platelet
counts below 80  109/L, and one instance of parvovirus
B19-induded reticulocytopenia with worsened anemia (absolute
reticulocyte count < 80  109/L with Hb concentration < 7 g/
dL) occurred. In all occurrences of presumed hematologic
toxicity, hydroxyurea treatment was held for 1 week, and blood
counts completely recovered. Treatment was restarted at the
same dose or at a dose reduced by 2.5 mg/kg if toxicity had been
recurrent. There was no evidence of renal or hepatic toxicity
(Table 1).

Hb (g/dL)
MCV (fL)
WBC (109/L)
ANC 109/L
Platelets (109/L)
Hb F (%)
Reticulocyte count (%)
LDH (U/L)
ALT (U/L)
Creatinine (mg/dL)
GFR (mL/min/sqm)
Hydroxyurea (mg/kg/day)

Hematologic Toxicity

Year 4

After 15 years of hydroxyurea therapy, hematologic
indices, including mean annual values for Hb, MCV, HbF,
reticulocyte count, WBC, and platelet counts showed sustained
long-term hydroxyurea effect (Table 1). HbF levels remained
above the expected values for untreated individuals with SCA of
the same age (Figure 2). Monthly MPR was available for the 5
subjects treated at St. Jude. Their median MPR between the 6th
and 15th year of treatment was 90% (range 88.2–97.4%).

Year 2

Hematologic Efficacy and Hydroxyurea
Adherence

Baseline

As of December 31, 2012, 8 of the original HUSOFT
subjects (all HbSS, 6 females and 2 males, median age 17.1
years, range 16.4–17.8 years) had received hydroxyurea continuously for a median of 15.9 years (range, 15.5–16.0 years).
After the initial 2 years of hydroxyurea therapy, their dose was
escalated to MTD and dose adjustments for weight gain were
performed. Their median dose after 15 years was 26.6 mg/kg/day
(range 18.0–33.1 mg/kg/day), a slight reduction from the initial
dose escalation to 30 mg/kg/day.6

TABLE 1. Annual Means for Laboratory Indices and Hydroxyurea Dose by Year of Treatment Among 8 Children With SCA Treated 15 Years

Patient Characteristics

Year 12

RESULTS

Notes: Results presented as mean  1 STD. All variables calculated for the 8 subjects who have been on continuous hydroxyruea for 15 years. ANC ¼ absolute neutrophil count, Hb ¼ hemoglobin,
HbF ¼ fetal hemoglobin, LDH ¼ lactate dehydrogenase, MCV ¼ mean corpuscular volume, WBC ¼ white blood cell count. Normal reference value for LDH ¼ 165 to 310 units/L.
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Long-term hydroxyurea-treated children
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FIGURE 2. Fetal hemoglobin (HbF) levels during extended hydroxyurea therapy. Children with SCA treated with hydroxyurea for a
minimum of 15 years have sustained HbF levels in comparison with untreated children. Legend: diamonds represent 8 children with SCA
treated with hydroxyurea for a minimum of 15 years, squares represent untreated American children,18 triangles untreated Jamaican
children,19 and circles untreated British children.20 HbF values depicted are mean (1 STD) for the populations.

albumin/g creatinine (range, 53–145). The mean GFR was
normal at 116.0  20.6 mL/min/m2, albeit decreased from Years
9 and 12 (Table 1). Hb oxygen saturation was normal (median
100%, range 99–100%).
MRI of the brain revealed 2 children with SCI. The first
was a male with bilateral frontal lesions diagnosed at 17 months
of age (at HUSOFT study entry) that have remained unchanged
for the past 15 years. The second was a female who developed a
small focus of increased MRI T2-weighted signal in the right
periatrial white matter at 7 years of age7 (5 years after starting
hydroxyurea); this lesion did not change in the subsequent
9 years. No subjects had cerebral artery stenosis on brain
MRA. TCD velocities were in the conditional range during
hydroxyurea therapy in 2 (25%) subjects in the HUSOFT group,
but later normalized; none had abnormal TCD velocities.

Acute Clinical Events
Life-time ACS and vaso-occlusive pain events were 5.1
events/100 patient-years and blood transfusion utilization was
7.3 packed red blood cell transfusions/100 patient/years. There
were no malignancies, strokes, or deaths among these subjects.

DISCUSSION
Hydroxyurea therapy is the only FDA-approved ‘‘antisickling’’ medication for adults with SCA, and the only one,
that is, commercially available (with off-label indication) for
children with SCA. In the most recent National Heart Lung and
Blood Institute (NHLBI) evidence-based guidelines, hydroxyurea is recommended for all children 9 months of age with
SCA, regardless of disease severity, to reduce disease-related
complications.11
Hydroxyurea has been shown to reduce vaso-occlusive
events (pain and ACS) in phase III randomized clinical trials in
both adults and children,2,3 but its long-term benefits in children
are incompletely characterized. Our data indicate that hydroxyurea therapy, when started at a very young age (<2 years) and
given for an extended period of time, appears safe and promotes

4
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the expected hematologic and clinical effects for more than
15 years. These subjects, who are now adolescents/young
adults, have had normal growth and development, are in school
at appropriate grade level, and continue to experience very few
vaso-occlusive episodes and minimal blood utilization. This is
the first cohort of children to be reported who have had
hydroxyurea therapy continuously prescribed for this length
of time.
Hematologic effects of hydroxyurea were sustained over
the prolonged period of drug exposure, which was more than
twice as long as previously reported.8 The median hydroxyurea
doses lightly decreased from 30 to 26.5 mg/kg/day, perhaps
reflecting the physiologic decrease in marrow cellularity that
occurs with increasing age, and/or changes in body habitus,
renal function, or muscle mass. There were no apparent cases of
tolerance or refractoriness to hydroxyurea therapy, as hematologic effects continued even after 15 years of drug exposure
among those with adequate drug adherence. This is consistent
with the lack of evidence for pharmacologic tolerance or
resistance discussed in a recent review.12
Organ dysfunction is an expected long-term complication
of SCA. Although no conclusions can be drawn from the small
cohort of HUSOFT patients, their current brain, kidney, and
spleen evaluations suggest some degree of protection from
dysfunction related to prolonged hydroxyurea exposure.
Finally, growth and development were normal for those treated
with long-term hydroxyurea. Pubertal onset occurred at the
expected age, contrasting with the published literature that
reports an average delay in pubertal development in SCA
children of approximately 2 years.13
An increased cancer risk in individuals with SCA who
utilize hydroxyurea has not been demonstrated in children or
adults. Cross-sectional and prospective studies (involving chromosomal karyotype, illegitimate VDJ recombination events,
cytotoxicity development, and genotoxicity measured by micronucleated reticulocyte formation) have failed to demonstrate
increases in mutagenesis when compared with measurements
made prior to initiation of therapy or with individuals who were
#
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receiving placebo.14– 17 Although no relationships have been
demonstrated to date, prospective monitoring of cancer risk, and
hydroxyurea genotoxicity should continue.
Our study has many limitations, including a small sample
size, no formal prospective treatment adherence assessment,
and lack of data on those who interrupted treatment prior to 15
years. Despite our efforts, we were not able to capture the
clinical and laboratory data of the HUSOFT participants who
discontinued hydroxyurea prior to 15 years. Therefore, we
cannot make comparisons of the incidence of events or laboratory findings between the original HUSOFT participants who
did not interrupt treatment and those who did, somewhat limiting the interpretation of long-term efficacy and safety results. In
addition, because these adolescents were followed at only 2
institutions, our results may not be generalizable. This study,
however, offers the strengths of prospective monitoring of
laboratory and organ function at fixed intervals in a unique
cohort of children who have been treated with hydroxyurea
from a very early age with consistent prolonged treatment.
In conclusion, our study showed that in a cohort of
children not selected for disease severity and treated with
hydroxyurea continuously since infancy for a minimum of
15 years, hematologic effects of the drug persist without major
toxicity. Growth is normal, and pubertal development timely.
Future research should focus on continued and long-term
exposure to hydroxyurea, as well as collection of data on those
who have intermittent use of this drug. As current generations
of individuals treated with hydroxyurea enter puberty and
mature into adulthood on this medication, its effects and
toxicities, including effects on fertility (especially spermatogenesis), must be monitored. The BABYHUG follow-up
observational studies (clinicaltrials.gov #NCT00890396 and
#NCT01783990) will be of great value in describing the longterm efficacy and toxicity of hydroxyurea in a larger cohort of
children who also have been treated since infancy, generally
without interruption. Adult studies, such as the MSH and
LaSHS, should continue to provide us with important information regarding the risks and benefits of hydroxyurea in older
individuals with SCA.
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